RemeGen’s Telitacicept and Disitamab Vedotin Enter China’s National Reimbursement Drug List for SLE and Gastric Cancer Treatment

YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitaci...

Full "IntellAsia: Resources" article